retatrutide latest clinical trial results Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Lilly's 'triple G' agonist triumphs

Suppress Appetite Improve Health Lose Weight Affordably Priced Weight Loss Special Unlock a Healthier You with GLP-1 and GLP-1+GIP Kick Start 2025 with these Early Bird Offers

Some users experience mild to moderate side effects, such as nausea and digestive issues, particularly during the first few weeks of treatment

Who Is Eligible, and What Support Do Patients Need

Skipping steps or accelerating the timeline almost always leads to intolerable nausea, vomiting, or diarrhea

Aegis Peptides offers free UK Tracked 24 delivery on all orders, helping research buyers receive their products quickly, securely and with tracking information for peace of mind

Trials to date have shown that GLP-1s may have beneficial effects on kidney function, especially relevant for T2D patients with chronic kidney disease (CKD)